---
audienceLevel: patient
cancerTypes:
- lung
- colorectal
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Encorafenib - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/encorafenib
version: v1
---

# Encorafenib - NCI

# Encorafenib

Placeholder slot

(EN-kor-A-feh-nib)

This page contains brief information about encorafenib
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Braftovi

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=235dfc38-0f0b-4037-b501-7a9f4294740c&audience=consumer)

## Use in Cancer

Encorafenib
is approved to be used with other drugs to treat patients whose cancer has a certain [mutation](/Common/PopUps/popDefinition.aspx?id=46063&version=Patient&language=English) in the *[BRAF](/Common/PopUps/popDefinition.aspx?id=561325&version=Patient&language=English)* gene, including:

- **[Colorectal cancer](/Common/PopUps/popDefinition.aspx?id=444983&version=Patient&language=English)** that has spread to other parts of the body. It is used:
- with [cetuximab](/Common/PopUps/popDefinition.aspx?id=45467&version=Patient&language=English) in adults who have received previous treatment
- with cetuximab and [mFOLFOX-6](/Common/PopUps/popDefinition.aspx?id=671827&version=Patient&language=English)¹
- **[Melanoma](/Common/PopUps/popDefinition.aspx?id=45135&version=Patient&language=English).** It is used with [binimetinib](/Common/PopUps/popDefinition.aspx?id=793872&version=Patient&language=English) in patients whose cancer cannot be removed by surgery or has spread to other parts of the body.
- **[Non-small cell lung cancer](/Common/PopUps/popDefinition.aspx?id=45323&version=Patient&language=English).** It is used with binimetinib in adults whose cancer has spread to other parts of the body.

¹This use is approved under FDA’s [Accelerated Approval Program](https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm). As a condition of approval, [confirmatory trial(s)](/Common/PopUps/popDefinition.aspx?id=799146&version=Patient&language=English) must show that encorafenib provides a clinical benefit in these patients.

Encorafenib
is also being studied in the treatment of other types of
cancer.

## More About Encorafenib

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/712549) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Encorafenib](https://medlineplus.gov/druginfo/meds/a618040.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Androgen Receptor May Explain Sex Differences in Melanoma Treatment Response](https://www.cancer.gov/news-events/cancer-currents-blog/2022/melanoma-treatment-androgen-receptor)

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Encorafenib](https://www.cancer.gov/research/participate/clinical-trials/intervention/C98283) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
